title: High reported treatment satisfaction in people with type 1 diabetes switching to latest generation insulin pump regardless of previous therapy.
abstract: The effects of transition by individuals with type 1 diabetes (T1D) to more recently available continuous glucose monitoring (CGM)-enabled insulin pumps from either multiple daily insulin injections (MDI) or older insulin pumps on treatment satisfaction have not been well studied. We conducted a survey to assess treatment satisfaction among users of the Animas(®) Vibe™ insulin pump, a latest generation insulin pump (LGIP) system (CGM-enabled), after switching from MDI or earlier generation insulin pumps. Individuals with T1D from 141 centers in 5 countries and 4 language areas participated in the survey. Treatment satisfaction was assessed by the Insulin Treatment Satisfaction Questionnaire (ITSQ), which was included in a 50-item online questionnaire that also assessed preference for using the LGIP compared with previous treatment and satisfaction with key LGIP features. A total of 356 individuals, ages 12-79 years, responded to the survey: mean (SD) age 38.4 (16.1) years; diabetes duration 19.1 (13.3) years; female 59%; previously treated with MDI 58%. Overall mean (SD) ITSQ scores were high among all respondents regardless of prior treatment: 95.1 (23.2) (scale: 0-132). No differences between previous-treatment groups were seen. Most (83%) of respondents rated the LGIP to be better than their previous insulin delivery system: "much better" (65%), "a bit better" (18%) regardless of age, and 95% would recommend using the LGIP to others. Use of the Animas Vibe was associated with high treatment satisfaction and perceived as a better method of insulin delivery regardless of previous insulin therapy or age.
authors.affiliation: Human Development and Health, University of Southampton, Southampton, UK katharine.barnard1@virginmedia.com.
authors.forename: Katharine D
authors.initials: KD
authors.lastname: Barnard
authors.affiliation: Froidevaux & Partner, Zurich, Switzerland.
authors.forename: Michael
authors.initials: M
authors.lastname: Bromba
authors.affiliation: Groene Hart Hospital, Gouda, Netherlands.
authors.forename: Mirja
authors.initials: M
authors.lastname: de Lange
authors.affiliation: Diabetology Department, AP-HP, Hôpital Pitié-Salpétrière, Paris, France.
authors.forename: Marine
authors.initials: M
authors.lastname: Halbron
authors.affiliation: LifeScan Inc, West Chester, PA, USA.
authors.forename: Brian L
authors.initials: BL
authors.lastname: Levy
authors.affiliation: Hôpital de Nanterre, Nanterre, France.
authors.forename: Marc
authors.initials: M
authors.lastname: Lévy
authors.affiliation: Diabetes Klinik, Bad Mergentheim, Germany.
authors.forename: Bernhard
authors.initials: B
authors.lastname: Lippmann-Grob
authors.affiliation: Lagan Valley Hospital, Lisburn, UK.
authors.forename: Kieran
authors.initials: K
authors.lastname: Walshe
authors.affiliation: Diabetes Clinic for Children and Adolescents, Muenster, Germany.
authors.forename: Ralph
authors.initials: R
authors.lastname: Ziegler
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007332:Insulin Infusion Systems; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011795:Surveys and Questionnaires; D055815:Young Adult
keywords: CGM; CSII; ITSQ; continuous glucose monitoring; insulin pump; treatment satisfaction